ABSTRACT

Introduction: The importance of erectile dysfunction (ED) diagnosis and treatment has been highlighted since the early 2000s. However, nearly 20 years after the first phosphodiesterase 5 inhibitor (PDE5i) was marketed, underdiagnosis and undertreatment of ED in the primary health care setting may still be present.

Aim: To assess the relative frequency of patients who are medically treated for ED before referral to specialized urology care. The secondary objectives were to evaluate possible reasons for non-treatment prior to referral and other signs of undertreatment, namely cardiovascular risk assessment and antihypertensive treatment.

Methods: 200 male patients referred for ED to specialist urology care by general practitioners were screened after consent between January 2016—December 2018. A full standardized medical and sexual history were taken. Previous medical treatment of ED, namely pharmacologic name and dosages, and cardiovascular risk factors were noted.

Main Outcome Measures: Of the 115 included patients, only 33.9% of patients had already taken PDE5i before referral, and none had taken alprostadil by intracavernous route.

Results: The mean patient age was 58.68 ± 10.01 years old. Only 45.2% had been prescribed the highest dose of PD5i. From the remaining untreated patients, only 19.7% had ≥3 cardiovascular risk factors, including 5.6% of patients who also presented moderate-to-severe stable or unstable angina requiring a stress test or cardiology assessment before treatment. Regarding the 54 patients with medical history of arterial hypertension, 43.4% and 30.2% were treated for hypertension with a diuretic and a beta blocker, respectively.

Conclusion: More focus on the primary healthcare continuous medical education regarding sexual dysfunction, namely ED, is needed because major undertreatment of ED is still present because low prescription of PD5i before referral is noted. Morgado A, Moura ML, Dinis P, et al. Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care. Sex Med 2019;7:177–183.

Key Words: Erectile Dysfunction; Undertreatment; Primary Health Care; General Practitioner

INTRODUCTION

The importance of erectile dysfunction (ED) diagnosis and treatment has been highlighted since the early 2000s due to the finding of an independent association between ED and coronary artery disease (CAD).1−4 Moreover, ED often precedes symptomatic CAD or its diagnosis, and ED is often described as a sentinel symptom of CAD.5 Furthermore, ED is known to be a side effect of common medications for diseases, such as arterial hypertension, and ED has a known effect on the quality of life.6−9 Moreover, its treatment has been shown to improve not only erectile function but also the quality of life10; thus, its diagnosis and treatment should be sought.

In Portugal, ED is a prevalent, age-related disease. A national survey published in 2011 disclosed that 26.0% of men >60 years old reported erection problems.11 The prevalence of ED and the availability of safe and efficacious first-line treatment has necessarily changed ED treatment from an exclusive specialty in either urology or psychiatry to also include primary health care providers. This shift in paradigm and the acknowledgement of the limited opportunities to learn sexual medicine in medical school and

Sex Med 2019;7:177–183
Erectile Function (IIEF-5). 20 Patients completed a basic translated validated version of the brief International Index of pills taken. Included patients were also asked to complete a also noted, namely pharmacologic name, dosage, and number of medications were noted. Previous medical treatment for ED was were excluded. Cardiovascular risk factors and concomitant diagnosis of ED and history of penile surgery other than circumcision were considered and agreed to participate. There was an important misdiagnosis of ED with 22.3% of the valid screens excluded from participating for a main diagnosis other than ED. Furthermore, 8.4% of those referred demonstrated spontaneous resolution of symptoms at the time of consultation (Table 1). The most common misdiagnosis was premature ejaculation (PE), with 10.6% of valid screened patients receiving this diagnosis.

RESULTS

From the 200 patients intended for screening, 179 were effectively screened, because 21 patients missed their appointment. Overall, 115 patients fulfilled all the inclusion and exclusion criteria and agreed to participate. There was an important misdiagnosis of ED with 22.3% of the valid screens excluded from participating for a main diagnosis other than ED. Furthermore, 8.4% of those referred demonstrated spontaneous resolution of symptoms at the time of consultation (Table 1). The most common misdiagnosis was premature ejaculation (PE), with 10.6% of valid screened patients receiving this diagnosis.
agreed to repeat an IIEF-5 at 6 months of treatment with PDE5i. Patient were referred for lack of PDE5i efficacy. Moreover, the highest dosage of the PDE5i prescribed (Table 3). Additionally, conducted medical treatment, and changes had also been suggested with medical treatment, and another 5.6% presented moderate-to-severe stable or unstable angina. Only 19.7% of the aforementioned group presented symptoms as assessed by a normal IIEF-5 score. The majority (73.0%) had resolution of symptoms at the highest dosage. The majority (73.0%) had resolution of symptoms as assessed by a normal IIEF-5 score (>21).

Regarding previously non-treated patients (66.1%, 76 patients), concomitant cardiovascular risk factors were analyzed. Only 19.7% of the aforementioned group presented ≥3 cardiovascular risk factors, excluding sex (Table 4), and only another 5.6% presented moderate-to-severe stable or unstable angina.

When previously treated patients were compared with untreated patients, there were no statistically significant differences in age, body mass index, baseline IIEF-5 score, and number of cardiovascular risk factors. There was no statistically significant difference in the distribution of ethnicity, marital status, education, work, hypertension, dyslipidemia, diabetes mellitus, history of CAD, smoking status, or obesity in univariate or multivariate analyses (Table 5).

**DISCUSSION**

Currently, there is still a lack of knowledge regarding the relationship between primary health care and specialized urology care in ED diagnosis and treatment. The few existent reports only address GP habits and intentions regarding ED diagnosis.

The mean age of the patients was 58.68 ± 10.01 years old, and the mean IIEF-5 score was 10.88 ± 4.37. The majority of patients had studied until fourth grade (49.6%) or ninth grade (35.6%) and were actively working (64.7%); 67.0% were married. Additional sociodemographic data are described in Table 2.

Regarding the 54 patients with medical history of arterial hypertension, 43.4% and 30.2% were treated for hypertension with a diuretic and a beta blocker, respectively. In addition, almost two-thirds (64.8%) were treated with either a diuretic or a beta blocker, whereas only one-third (37.5%) of the patients treated with a beta blocker were receiving nebivolol.

Regarding lifestyle changes, only 26.0% indicated that lifestyle changes had also been suggested with medical treatment, and 4.3% indicated that only the former was suggested. Regarding cardiovascular risk factor optimization, 86.8% had normal or controlled blood pressure, whereas 84.2% had normal fasting glycemia or controlled glycated hemoglobin. Additionally, 71% had a normal or controlled lipid profile.

Regarding previous medical treatment for ED, only 33.9% were previously treated for ED and, if all screened patients were considered, only 29.0% of patients would have been previously treated for ED. The most common previous treatment for ED was sildenafil (42.1%). 45.2% of patients were treated at the highest dosage of the PDE5i prescribed (Table 3). Moreover, only 2 patients (5.2%) were on alprostadil cream, and no patient had any form of intracavernous treatment. Only 1 (2.5%) patient had been treated with a daily low-dose tadalafil. All except 1 patient were referred for lack of PDE5i efficacy. 26 patients agreed to repeat an IIEF-5 at 6 months of treatment with PDE5i

### Table 1. Description of patients excluded from the primary analysis

| Reason for Exclusion                      | % of row total (n) |
|-------------------------------------------|--------------------|
| Excluded for main diagnosis other than ED | 20.9% (40)         |
| Premature ejaculation                     | 10.6% (19)         |
| Peyronie’s disease                        | 3.4% (6)           |
| Diminished libido                         | 3.4% (6)           |
| Anorgasnia                                | 1.7% (3)           |
| Retrograde ejaculation                    | 1.1% (2)           |
| Anteporta ejaculation                     | 1.1% (2)           |
| Painful ejaculation                       | 0.6% (1)           |
| Low volume ejaculation                    | 0.6% (1)           |
| Spontaneous resolution of symptoms       | 8.4% (15)          |
| Excluded for previous penile surgery     | 2.8% (5)           |
| Penile prosthesis                        | 2.8% (5)           |
| Refusal to participate                    | 2.0% (4)           |

| Table 2. Patient characteristics |
|----------------------------------|
| **Age, mean ± SD**              | 58.6 ± 10.0 yrs |
| **Ethnicity**                   |                |
| White, % (n)                    | 99.1% (114)    |
| Black, % (n)                    | 0.9% (1)       |
| **Marital status**              |                |
| Single, % (n)                   | 5.2% (6)       |
| Married, % (n)                  | 67.0% (77)     |
| Divorced, % (n)                 | 14.8% (17)     |
| Widowed, % (n)                  | 13.0% (15)     |
| **Education**                   |                |
| Until 4th grade, % (n)          | 49.6% (57)     |
| Until 9th grade, % (n)          | 35.6% (41)     |
| Until high school graduation, % (n) | 9.6% (11)   |
| Some college or college degree, % (n) | 5.2% (6)    |
| **Work**                        |                |
| Employed, % (n)                 | 64.3% (74)     |
| Unemployed, % (n)               | 5.2% (6)       |
| Retired, % (n)                  | 30.4% (35)     |
| **Body mass index, mean ± SD**  | 28.6 ± 3.9 kg/m² |
| Baseline IIEF-5, mean ± SD      | 10.8 ± 4.3     |
| **Number of CV risk factors, mean ± SD** | 1.84 ± 1.34 |
| Arterial hypertension, % (n)    | 48.6% (54)     |
| Dyslipidemia, % (n)             | 44.1% (49)     |
| Diabetes mellitus, % (n)        | 39.6% (44)     |
| Obesity, % (n)                  | 32.4% (22)     |
| History of CAD, % (n)           | 10.1% (11)     |
| Active smoking, % (n)           | 30.7% (27)     |
| Mental health disorder, % (n)   | 9.2% (10)      |

### Table 3.

| Description of patients excluded from the primary analysis |
|-----------------------------------------------------------|
| % of row total (n)                                        |
| Excluded for main diagnosis other than ED                 | 20.9% (40) |
| Premature ejaculation                                     | 10.6% (19) |
| Peyronie’s disease                                        | 3.4% (6)   |
| Diminished libido                                         | 3.4% (6)   |
| Anorgasnia                                                | 1.7% (3)   |
| Retrograde ejaculation                                    | 1.1% (2)   |
| Anteporta ejaculation                                     | 1.1% (2)   |
| Painful ejaculation                                       | 0.6% (1)   |
| Low volume ejaculation                                    | 0.6% (1)   |
| Spontaneous resolution of symptoms                        | 8.4% (15)  |
| Excluded for previous penile surgery                     | 2.8% (5)   |
| Penile prosthesis                                         | 2.8% (5)   |
| Refusal to participate                                    | 2.0% (4)   |

CAD = coronary artery disease; CV = cardiovascular; IIEF-5 = International Index of Erectile Function.
and treatment.\textsuperscript{15,16,18,22} These reports often highlight discomfort, lack of knowledge, and time constraints from doctors to address sexual dysfunctions. Since the introduction of the first PDE5i in the late 1990s, there has been huge support from the pharmaceutical industry to gather medical and patient information regarding ED and other sexual dysfunction. There was always a special focus in the primary health care training, because ED was and still is a prevalent disease. Hopefully, some of the early conclusions regarding the primary health care setting may not hold true after the golden years of the pharmacologic “sex revolution.”

In the present study, rather than intentions and habits of GPs, we have looked at their actions appraising why and how patients with ED are referred to specialized urology care in real clinical practice. A very important topic is covered in this study, the possible undertreatment of ED.

It is known that male sexual dysfunction, especially ED and PE, can sometimes be confounded by both patients and doctors.\textsuperscript{23} When looking at excluded patients, the majority were excluded, as the main diagnosis was other than ED, with PE being the most common misdiagnosis. The magnitude of the latter does not seem to be discordant with data from other studies regarding both misdiagnosis or co-diagnosis of ED and PE.\textsuperscript{24,25} Given the limited time today’s general practitioners have with a patient and patient’s limited ability to report and describe symptoms, among other reasons, the complaint of difficulty in maintaining an erection can often be left unexplored and straightforward interpreted as a symptom of ED, rather than PE. Erectile function was normal in all of these patients.

Unfortunately, there is clearly a major undertreatment of ED before referral. The common patient of our study is a middle-aged man with a couple of cardiovascular risk factors and the consequent treatment medication. Some antihypertensive medications are known to cause or aggravate ED,\textsuperscript{26} namely thiazide diuretics, loop diuretics, and beta blockers, with the sole exception of nebivolol.\textsuperscript{27,28} Other classes seem to have no effect on erectile function, and angiotensin II receptor blockers might even have a positive effect.\textsuperscript{29} In Portuguese recommendations to GPs, thiazide diuretics, renin-angiotensin system modulators, and calcium channel blockers are all first-line options, whereas beta blockers should only be used in cases of concomitant heart disease or in younger patients.\textsuperscript{30} Moreover, GPs are reminded that side effects and patient-associated conditions should be considered when initially choosing an antihypertensive class of medication.

Before starting medical treatment or referral, it is important to consider lifestyle changes and cardiovascular risk optimization, to review patient medication thoroughly, and, if possible, to remove or change medication that is known to cause or aggravate ED, such as antihypertensive agents. These interventions alone have been shown to improve ED.\textsuperscript{31} Almost half of our population had a medical history of arterial hypertension, and, from these patients, almost two-thirds were treated with either a diuretic or a beta blocker for arterial hypertension. Most of those patients on diuretics were on thiazides, whereas only one-third of those treated with a beta blocker were on nebivolol. There is clearly margin for improvement, because both diuretics and beta blockers can often be swapped for other antihypertensive classes with a better side-effect profile on erectile function. In the specific case of beta blockers, these can even be replaced by nebivolol, if needed, with a better side-effect profile.\textsuperscript{32,33}

Although lifestyle changes were only reportedly suggested to roughly one-third of the patients, the vast majority had its cardiovascular risk factors optimized as assessed by blood pressure, glycemic control, and the lipid profile, and only one-third were still active smokers. Given the limited time available by Portuguese GPs on appointments, the modification of complaints associated with high morbidity/high mortality, rather than the limited to quality-of-life ones, is often a major concern in their daily practice. However, this usually comes at the expense of medical treatment and not lifestyle intervention, as shown by the low reported suggestions for lifestyle intervention.

### Table 3. Previous treatment by pharmacologic name, dosage, and number of pills/tries for erectile dysfunction.

| Pharmacologic name | Relative frequency, % (n) |
|--------------------|--------------------------|
| Sildenafil          | 42.1% (16)               |
| Avanafil           | 23.6% (9)                |
| Tadalafil          | 26.3% (10)               |
| Vardenafil         | 18.4% (7)                |
| Alprostadil cream  | 5.2% (2)                 |
| PDE5i dosage       |                          |
| Highest            | 45.2% (14)               |
| Intermediate       | 35.5% (11)               |
| Lowest             | 19.3% (6)                |
| Reason for referral|                          |
| Lack of efficacy of PDE5i | 97.4% (37) |
| Adverse effect of PDE5i | 2.6% (1)        |

PDE5i = phosphodiesterase 5 inhibitor.

### Table 4. Cardiovascular risk factors in previously untreated patients (n = 76 patients)

| Arterial hypertension | % of row total (n) |
|-----------------------|--------------------|
| 44.6% (33)            |
| Dyslipidemia          | 40.8% (31)         |
| Diabetes mellitus     | 36.8% (28)         |
| Obesity               | 14.4% (11)         |
| History of CAD        | 11.8% (9)          |
| Active smoking        | 26.3% (20)         |
| Number of CV risk factors |     |
| 0                     | 23.7% (18)         |
| 1                     | 25.0% (19)         |
| 2                     | 31.6% (24)         |
| ≥3                    | 19.7% (15)         |

CAD = coronary artery disease; CV = cardiovascular.
Only roughly one-third of our population has been previously treated for ED. This relative frequency is clearly low. As mentioned, ED is a prevalent disease, and effective, safe, and affordable medical treatment is widely available; thus, it would be expected that the largest burden of ED care would rely on the GPs, and only refractory ED patients would be referred to specialized urology care. Although it is a matter of current debate regarding whether GPs or only urologists should start second-line intracavernous therapy, it is clear that, in the absence of contraindication, PDE5i at the highest dosage should be tried and tested, preferably 8 times before a conclusion is drawn. In the present study, only 45.2% of previously treated patients were at the highest dosage of PDE5i, whereas no patient was treated with any intracavernous treatment. These data possibly reflect premature referral to specialized care rather than a true lack of response to PDE5i in some patients and indicate undertreatment of ED, because >50% of the patients did not receive appropriate treatment at the highest dosage approved. Unfortunately, few valid answers were noted on the number of pills taken, but the majority reported having only tried ≤4 pills before referral (data not shown). Interestingly, when retreated with PDE5i at the highest dosage, most of the 26 patients who agreed to repeat the IIEF-5 at 6 months had a normal IIEF-5 score. Altogether, these data further underline that, even in previously treated patients, there is undertreatment, either in the form of insufficient attempts, inadequate dosage, or poor patient education on how and when to take PDE5i.

Among the several barriers GPs face regarding not discussing sexual health problems with CAD patients, a patient perceived as “too ill” for treatment was 1 of the most common replies in 1 report, even though PDE5i is currently well established for cardiovascular safety. In our study, cardiovascular risk factors were common among previously non-treated patients (Table 4). However, roughly one-quarter did not present any cardiovascular risk factor, excluding sex, and even fewer presented ≥3 risk factors or moderately stable or unstable angina requiring a stress test or a cardiologist evaluation. Thus, the majority of patients could have probably been treated for ED with PDE5i, possibly avoiding referral for specialized care.

If successful treatment had occurred in previously treated patients, a selection bias would have been observed, because fewer organic ED patients would have responded to treatment, leaving possibly less-healthy patients for referral. However, there was no statistically significant difference between previously treated and
untreated patients, which hints at possible undertreatment and premature referral. Additionally, 26 of the initial 48 previously treated patients were treated with PDE5i for 6 months, and the majority had resolution of symptoms as assessed by the IIEF-5 score.

To our knowledge, the present study is the first to assess GP actions rather than intentions or habits for ED care in a prospective manner, with almost 200 patients screened, and roughly half included. However, our study presents some limitations, because it can suffer from recall bias regarding previous ED treatment. After permission by the patient, the patient chart and past prescription history were reviewed and double-checked with patients to minimize this potential bias. Even though our center is a tertiary academic hospital with a vast area of influence, our study still stands as a single-center study, and local health policies might influence results, which may limit generalizability. Moreover, the study population is relatively small, so relative frequencies can suffer from bias, whereas comparisons can present type 2 errors. However, the study population is comparable in bio-socio-demographic data from a much larger Portuguese study in ED patients treated in primary health care, which adds validity to our sample data. The study could have also collected information regarding the GP profile to establish further comparisons and conclusions.

CONCLUSIONS

The present study clearly shows that a sizable proportion of patients with ED are being undertreated in the primary health care setting, as shown by the low or inadequate prescription of PDE5i before referral. Moreover, patient-related cardiovascular risk factors do not seem to be the motive for undertreatment, because the majority of non-treated patients lack a formal contraindication for ED treatment.

Corresponding Author: Afonso Morgado, Serviço de Urologia, Centro Hospitalar de São João, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal. Tel: 351 225 512 100; Fax: 351 225 025 766; E-mail: luisafonsomorgado@gmail.com

Conflict of Interest: The authors report no conflicts of interest.

Funding: None.

STATEMENT OF AUTHORSHIP

Category 1
(a) Conception and Design
Afonso Morgado; Maria Leonor Moura; Carlos Martins Silva
(b) Acquisition of Data
Afonso Morgado; Maria Leonor Moura

Category 2
(a) Drafting the Article
Afonso Morgado

(b) Revising It for Intellectual Content
Afonso Morgado; Paulo Dinis; Carlos Martins Silva

Category 3
(a) Final Approval of the Completed Article
Afonso Morgado; Maria Leonor Moura; Paulo Dinis; Carlos Martins Silva

REFERENCES
1. Laumann EO, Paik A, Rosen RC. The epidemiology of erectile dysfunction: Results from the National Health and Social Life Survey. Int J Impot Res 1999;11(Suppl. 1):S560-S564.
2. Guo W, Liao C, Zou Y, et al. Erectile dysfunction and risk of clinical cardiovascular events: A meta-analysis of seven cohort studies. J Sex Med 2010;7:2805-2816.
3. Fang SC, Rosen RC, Vita JA, et al. Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey. J Sex Med 2015;12:100-108.
4. Fan Y, Hu B, Man C, et al. Erectile dysfunction and risk of cardiovascular and all-cause mortality in the general population: A meta-analysis of cohort studies. World J Urol 2018;36:1681-1689.
5. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-364; discussion 364-365.
6. Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med 1998;13:159-166.
7. De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked. Diabetes Care 2002;25:284-291.
8. Penson DF, Latini DM, Lubeck DP, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-1099.
9. Rosas SE, Joffe M, Franklin E, et al. Association of decreased quality of life and erectile dysfunction in hemodialysis patients. Kidney Int 2003;64:232-238.
10. Tang WH, Zhuang X-J, Ma L-L, et al. Effect of sildenafil on erectile dysfunction and improvement in the quality of sexual life in China: A multi-center study. Int J Clin Exp Med 2015;8:11539-11543.
11. Vendeira PS, Monteiro Pereira N, Tomada N, et al. Episex-PT: Epidemiologia das disfunções sexuais masculinas em Portugal. Isex Cadernos De Sexologia 2011;0(4):15-22.
12. Morreale MK, Arfken CL, Balon R. Survey of sexual education among residents from different specialties. Acad Psychiatr 2010;34:346-348.
13. Hatzichristou D, Rosen RC, Derogatis LR, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7(Pt 2):337-348.

14. Mulhall JP, Giraldi A, Hackett G, et al. The 2018 revision to the process of care model for management of erectile dysfunction. J Sex Med 2018;15:1434-1445.

15. Ribeiro S, Alarcão V, Simões R, et al. General practitioners’ procedures for sexual history taking and treating sexual dysfunction in primary care. J Sex Med 2014;11:386-393.

16. Byrne M, Doherty S, McGee HM, et al. General practitioner views about discussing sexual issues with patients with coronary heart disease: A national survey in Ireland. BMC Fam Pract 2010;11:40.

17. Aschka C, Himmel W, Ittner E, et al. Sexual problems of male patients in family practice. J Fam Pract 2000;50:773-778.

18. Alarcão V, Ribeiro S, Miranda FL, et al. General practitioners’ knowledge, attitudes, beliefs, and practices in the management of sexual dysfunction-results of the Portuguese SEXOS study. J Sex Med 2012;9:2508-2515.

19. Vik A, Brekke M. Do patients consult their GP for sexual concerns? A cross sectional explorative study. Scand J Prim Health Care 2017;35:373-378.

20. Pechorro PS, Calvinho AM, Pereira MN, et al. Validação de uma versão portuguesa do Índice Internacional de Função Eréctil-5 (IIEF-5). Revista Internacional de Andrología 2011;9:3-9.

21. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012;87:766-778.

22. Temple-Smith MJ, Mulvey G, Keogh L. Attitudes to taking a sexual history in general practice in Victoria, Australia. Sex Transm Infect 1999;75:41-44.

23. Shabsigh R. Diagnosing premature ejaculation: A review. J Sex Med 2006;3(Suppl. 4):318-323.

24. Corona G, Rastrelli G, Limoncin E, et al. Interplay between premature ejaculation and erectile dysfunction: A systematic review and meta-analysis. J Sex Med 2015;12:2291-2300.

25. Saltz TR, Serefoglu EC. The epidemiology of premature ejaculation. Transl Androl Urol 2016;5:409-415.

26. Chryssant SG. Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol 2015;30:383-390.

27. Brixius K, Middeke M, Lichtenthal A, et al. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): Benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007;34:327-331.

28. Martínez-Salamanca JL, La Fuente JM, Cardoso J, et al. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO:cGMP pathway. J Sex Med 2014;11:1182-1192.

29. Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction in diabetic patients: A clinical trial. Int J Impot Res 2012;24:217-220.

30. Saúde D-G. Abordagem Terapeútica da Hipertensão Arterial; Available at: http://nocs.pt/wp-content/uploads/2015/11/Abordagem-Terapêutica-da-Hipertensão-Arterial.pdf; Accessed November 1, 2018.

31. Allen MS, Walter EE. Health-related lifestyle factors and sexual dysfunction: A meta-analysis of population-based research. J Sex Med 2018;15:458-475.

32. Al Khaja KA, Sequeira RP, Alkhaja AK, et al. Antihypertensive drugs and male sexual dysfunction: A review of adult hypertension guideline recommendations. J Cardiovasc Pharmacol Ther 2016;21:233-244.

33. Patel JP, Lee EH, Mena-Hurtado CI, et al. Evaluation and management of erectile dysfunction in the hypertensive patient. Curr Cardiol Rep 2017;19:89.

34. Teles AG, Carreira M, Alarcão V, et al. Prevalence, severity, and risk factors for erectile dysfunction in a representative sample of 3,548 Portuguese men aged 40 to 69 years attending primary healthcare centers: Results of the Portuguese Erectile Dysfunction Study. J Sex Med 2008;5:1317-1324.